• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Mountain Crest Acquisition Corp. II

    9/27/21 5:15:42 PM ET
    $MCAD
    Finance
    Get the next $MCAD alert in real time by email
    SC 13G 1 sc13g.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. )*

    MOUNTAIN CREST ACQUISITION CORP. II
    (Name of Issuer)

    Common Stock, $0.0001 par value per share
    (Title of Class of Securities)

    62402D105
    (CUSIP Number)

    September 14, 2021
    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    *
     
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No. 62402D105
     
    Page 2 of 7 Pages
                 
    1
     
    NAME OF REPORTING PERSON
    Tempo Opportunities Fund LLC
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
    (a) ☐  (b) ☐
    3
     
    SEC USE ONLY
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5
     
    SOLE VOTING POWER
    0
     
    6
     
    SHARED VOTING POWER
    500,085
     
    7
     
    SOLE DISPOSITIVE POWER
    0
     
    8
     
    SHARED DISPOSITIVE POWER
    500,085
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    500,085
    10
     
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    6.6%
    12
     
    TYPE OF REPORTING PERSON (See Instructions)
    OO




    CUSIP No. 62402D105
     
    Page 3 of 7 Pages
                 
    1
     
    NAME OF REPORTING PERSON
    RPO LLC
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
    (a) ☐  (b) ☐
    3
     
    SEC USE ONLY
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5
     
    SOLE VOTING POWER
    0
     
    6
     
    SHARED VOTING POWER
    500,085
     
    7
     
    SOLE DISPOSITIVE POWER
    0
     
    8
     
    SHARED DISPOSITIVE POWER
    500,085
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    500,085
    10
     
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    6.6%
    12
     
    TYPE OF REPORTING PERSON (See Instructions)
    OO



         
    CUSIP No. 62402D105
     
    Page 4 of 7 Pages
                 
    1
     
    NAME OF REPORTING PERSON
    J. David Rogers
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
    (a) ☐  (b) ☐
    3
     
    SEC USE ONLY
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5
     
    SOLE VOTING POWER
    0
     
    6
     
    SHARED VOTING POWER
    500,085
     
    7
     
    SOLE DISPOSITIVE POWER
    0
     
    8
     
    SHARED DISPOSITIVE POWER
    500,085
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    500,085
    10
     
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    6.6%
    12
     
    TYPE OF REPORTING PERSON (See Instructions)
    IN



    Item 1.


    (a)
    Name of Issuer:

    Mountain Crest Acquisition Corp. II (the “Issuer”)


    (b)
    Address of Issuer’s Principal Executive Offices:

    311 West 43rd Street, 12th Floor, New York, NY 10036

    Item 2.


    (a)
    Name of Person Filing:

    This Schedule 13G is jointly filed by Tempo Opportunities Fund LLC (the "TOF"), RPO LLC and J. David Rogers (collectively, the “Reporting Persons”).

    RPO LLC is the managing member of TOF.  RPO LLC is controlled by Mr. Rogers.


    (b)
    Address of Principal Business Office, or if none, Residence:

    The principal business address of each of the Reporting Persons is 60 Sunswyck Rd, Darien, CT 06820.


    (c)
    Citizenship:

    Each of TOF and RPO LLC is a Delaware limited liability company.

    Mr. Rogers is a citizen of the United States of America.


    (d)
    Title of Class of Securities:

    Common Stock, $0.0001 par value per share (“Common Stock”)


    (e)
    CUSIP Number:

    62402D105

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable

    Item 4. Ownership.


    (a)
    Amount beneficially owned:

    Each of the Reporting Persons may be deemed to be the beneficial owner of the shares of Common Stock listed on such Reporting Person’s cover page.

    As of September 27, 2021, TOF directly held 500,085 shares of Common Stock.


    (b)
    Percent of class:

    Each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of the shares of Common Stock listed on such Reporting Person’s cover page. Calculations of the percentage of shares beneficially owned assume 7,557,500 shares of Common Stock outstanding as of August 19, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 20, 2021.




    (c)
    Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote:

                See each cover page hereof.

    (ii) Shared power to vote or to direct the vote:

                See each cover page hereof.

    (iii) Sole power to dispose or to direct the disposition of:

                 See each cover page hereof.

    (iv) Shared power to dispose or to direct the disposition of:

                 See each cover page hereof.

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable

    Item 8. Identification and Classification of Members of the Group.

    Not applicable

    Item 9. Notice of Dissolution of Group.

    Not applicable

    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.





    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Dated: September 27, 2021

     
    TEMPO OPPORTUNITIES FUND LLC
           
     
    By:
     /s/ J. David Rogers
     
     
    Name:  
     J. David Rogers
     
     
    Title:
     Member  
           
           
     
    RPO LLC
           
     
    By:
     /s/ J. David Rogers  
     
    Name:
     J. David Rogers  
     
    Title:
     Managing Member
     
           
           
     
    J. DAVID ROGERS
           
     
    By:
     /s/ J. David Rogers
     
     
    Name:
    J. David Rogers
     
           



    Get the next $MCAD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MCAD

    DatePrice TargetRatingAnalyst
    7/29/2021$19.00Buy
    Lake Street
    More analyst ratings

    $MCAD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Better Therapeutics Closes Business Combination and Debuts on Nasdaq

      Trading to commence on Nasdaq on Oct. 29, 2021, under the ticker symbol BTTX Better Therapeutics, Inc., a prescription digital therapeutics (PDT) company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the completion of its business combination with Mountain Crest Acquisition Corp II (NASDAQ:MCAD, "Mountain Crest II"))), a publicly traded special purpose acquisition corporation or SPAC. The resulting combined company will commence trading its shares on Nasdaq under the ticker symbol "BTTX" on October 29, 2021. The shareholders of Mountain Crest Acquisition Corp II approved the transaction at a special meeting held on October

      10/29/21 8:00:00 AM ET
      $MCAD
      Finance
    • Mountain Crest Acquisition Corp. II Stockholders Approve Business Combination with Better Therapeutics Inc.

      NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ:MCAD) (the "Company"), a publicly traded special purpose acquisition company, announced today that in a special meeting of stockholders on October 27, 2021, its stockholders voted to approve its proposed business combination (the "business combination") with Better Therapeutics Inc. ("Better Therapeutics"), a company engaged in developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The business combination is expected to close on October 28, 2021, subject to the satisfaction of certain customary closing conditions. As part of the consummation o

      10/27/21 4:44:29 PM ET
      $MCAD
      Finance
    • Mountain Crest Acquisition Corp. II and Better Therapeutics, Inc. Announce Registration Statement Effectiveness and Scheduled Special Meeting to Approve Business Combination on October 27, 2021

      NEW YORK and SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ:MCAD, "Mountain Crest II"))), a publicly-traded special purpose acquisition company and Better Therapeutics, Inc. ("Better Therapeutics"), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that MCAD's registration statement on Form S-4 (File No. 333-255493) relating to the previously announced merger of MCAD and Better Therapeutics has been declared effective by the U.S. Securities and Exchange Commission as of October 12, 2021. MCAD also announced that it will hold its special m

      10/12/21 8:00:04 PM ET
      $MCAD
      Finance

    $MCAD
    Leadership Updates

    Live Leadership Updates

    See more
    • Better Therapeutics Appoints Dr. Risa Lavizzo-Mourey to its Board of Directors

      Better Therapeutics, Inc., a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Dr. Risa Lavizzo-Mourey to its board of directors; she will also serve as Compensation Committee chair. "Dr. Lavizzo-Mourey brings critical insights into health policy, as well as her background as a primary care physician at a critical juncture for Better Therapeutics," said David Perry, co-founder and chairman of Better Therapeutics. "Her experience and counsel will help us establish our prescription digital therapeutics as the new standard of care for people with cardiometabolic diseases.

      4/20/21 8:00:00 AM ET
      $MRK
      $GE
      $INTC
      $MCAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Consumer Electronics/Appliances
      Technology

    $MCAD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Mountain Crest Acquisition Corp. II

      SC 13D - Better Therapeutics, Inc. (0001832415) (Subject)

      11/8/21 5:28:53 PM ET
      $MCAD
      Finance
    • SEC Form SC 13D filed by Mountain Crest Acquisition Corp. II

      SC 13D - Better Therapeutics, Inc. (0001832415) (Subject)

      11/8/21 5:26:04 PM ET
      $MCAD
      Finance
    • SEC Form SC 13G filed by Mountain Crest Acquisition Corp. II

      SC 13G - Better Therapeutics, Inc. (0001832415) (Subject)

      11/8/21 1:11:00 PM ET
      $MCAD
      Finance

    $MCAD
    SEC Filings

    See more
    • Mountain Crest Acquisition Corp. II filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status

      8-K - Better Therapeutics, Inc. (0001832415) (Filer)

      11/3/21 5:26:13 PM ET
      $MCAD
      Finance
    • SEC Form 25-NSE filed by Mountain Crest Acquisition Corp. II

      25-NSE - Mountain Crest Acquisition Corp II (0001832415) (Subject)

      10/28/21 4:10:53 PM ET
      $MCAD
      Finance
    • SEC Form 425 filed by Mountain Crest Acquisition Corp. II

      425 - Mountain Crest Acquisition Corp II (0001832415) (Subject)

      10/27/21 5:21:36 PM ET
      $MCAD
      Finance

    $MCAD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Heinen Mark claimed ownership of 6,667 shares

      3 - Better Therapeutics, Inc. (0001832415) (Issuer)

      11/1/21 8:35:22 PM ET
      $MCAD
      Finance
    • SEC Form 4: Perry David P bought $2,512,432 worth of shares (251,536 units at $9.99) and was granted 10,578,501 shares

      4 - Better Therapeutics, Inc. (0001832415) (Issuer)

      11/1/21 8:55:45 PM ET
      $MCAD
      Finance
    • SEC Form 3: New insider Parker Geoffrey M. claimed ownership of 33,333 shares

      3 - Better Therapeutics, Inc. (0001832415) (Issuer)

      11/1/21 8:30:59 PM ET
      $MCAD
      Finance

    $MCAD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Mountain Crest Acquisition Corp. II with a new price target

      Lake Street initiated coverage of Mountain Crest Acquisition Corp. II with a rating of Buy and set a new price target of $19.00

      7/29/21 9:53:58 AM ET
      $MCAD
      Finance